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Abstract
Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-
integrated part of the clinical care of multiple sclerosis (MS) in several European countries.
ADA data generated in Europe during the more than 10 years of ADA monitoring in MS
patients treated with interferon beta (IFNβ) and natalizumab have been pooled and charac-
terized through collaboration within a European consortium. The aim of this study was to
report on the clinical practice of ADA testing in Europe, considering the number of ADA tests
performed and type of ADA assays used, and to determine the frequency of ADA testing
against the different drug preparations in different countries. A common database platform
(tranSMART) for querying, analyzing and storing retrospective data of MS cohorts was set
up to harmonize the data and compare results of ADA tests between different countries.
Retrospective data from six countries (Sweden, Austria, Spain, Switzerland, Germany and
Denmark) on 20,695 patients and on 42,555 samples were loaded into tranSMART includ-
ing data points of age, gender, treatment, samples, and ADA results. The previously
observed immunogenic difference among the four IFNβ preparations was confirmed in this
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large dataset. Decreased usage of the more immunogenic preparations IFNβ-1a subcuta-
neous (s.c.) and IFNβ-1b s.c. in favor of the least immunogenic preparation IFNβ-1a intra-
muscular (i.m.) was observed. The median time from treatment start to first ADA test
correlated with time to first positive test. Shorter times were observed for IFNβ-1b-Extavia
s.c. (0.99 and 0.94 years) and natalizumab (0.25 and 0.23 years), which were introduced on
the market when ADA testing was already available, as compared to IFNβ-1a i.m. (1.41 and
2.27 years), IFNβ-1b-Betaferon s.c. (2.51 and 1.96 years) and IFNβ-1a s.c. (2.11 and 2.09
years) which were available years before routine testing began. A higher rate of anti-IFNβ
ADA was observed in test samples taken from older patients. Testing for ADA varies
between different European countries and is highly dependent on the policy within each
country. For drugs where routine monitoring of ADA is not in place, there is a risk that some
patients remain on treatment for several years despite ADA positivity. For drugs where a
strategy of ADA testing is introduced with the release of the drug, there is a reduced risk of
having ADA positive patients and thus of less efficient treatment. This indicates that poten-
tial savings in health cost might be achieved by routine analysis of ADA.
Introduction
Immunogenicity of biotechnology-derived proteins (BPs) is of increasing concern in modern
medicine, but there are different opinions on whether testing for anti-drug antibodies (ADA)
should be an integrated part of clinical routine or not. The different standpoints have ranged
from that ADA testing adds essential information used for treatment decision, to that the reap-
pearance of clinical symptoms would lead to a change of treatment regardless of ADA testing.
Since ADA can develop neutralizing characteristics that reduces the efficacy of a drug, it is
important to have the tools ready to assess the potential immunogenicity of new drugs released
on the market. ADA testing is also of importance for determining the immunogenicity and
safety profiles in clinics in order to issue guidelines on how to give patients the best treatment
scheme while also making sure that the money spent by the clinics is used efficiently.
For treatment of multiple sclerosis (MS), some European countries, but not all, have had
ADA testing as an integrated part of clinical practice. The disease modifying drug interferon
beta (IFNβ) is a first-line treatment in MS that reduces the relapse rate, new lesion formation
and disability accumulation over time [1–3]. There are two different types of IFNβ products:
IFNβ-1a that is given either intramuscular (i.m.) at 30 μg once weekly (Avonex1, released in
Europe in 1997) or subcutaneous (s.c.) at 22 μg or 44 μg three times weekly (Rebif1, released
in Europe in 1998), and the two identical IFNβ-1b preparations given s.c. at 250 μg every other
day (Betaferon1 and Extavia1, released in Europe in 1995 and 2008 respectively). The immu-
nogenicity is known to differ between these preparations and this could be influenced by vari-
ous drug- and patient-related factors, e.g. dosing and frequency, aggregate content and genetic
background [4,5]. Neutralizing ADA (NAb) develop in up to 47% of patients using IFNβ-1b
and up to 28% and 6% for those treated with s.c. IFNβ-1a and i.m. IFNβ-1a, respectively [4].
MS patients have been treated with IFNβ since the 1990s, but the clinical practice of testing
for ADA and NAbs against the drug varies between countries. In Denmark it was a mandatory
part of the treatment regime from the beginning in 1996, while in other countries it is only
used when there is an indication of treatment failure. In Sweden the tests were provided for
free between 2003 and 2005 and later paid by the clinics. In Austria it was paid by the clinics
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from the beginning and in other countries (Switzerland, Spain and Germany) testing has only
been provided as part of research projects. Different ADA assays have been used and these
have varied over time, even within a country. Austria, Denmark, Spain, Switzerland and Swe-
den have used NAb tests both for screening and titration. In Germany all patients were first
screened with an enzyme linked immunosorbent assay (ELISA)-based ADA test and then con-
firmed and titrated with a NAb test.
When the monoclonal antibody natalizumab (Tysabri1) became available as a treatment
for MS after reintroduction in 2006, a test for ADA was developed by Biogen Idec (Maine Bio-
technology Services Inc., Portland, ME, USA) and provided to most countries from the begin-
ning. The same bridging ELISA method for ADA detection was used in all laboratories
included in this study, and yearly controls of 20 blinded test samples were used to ensure equal
performance of the test in different laboratories. The cut-point for ADA positivity in this assay
is set to a level that corresponds to neutralizing capacity of the antibodies [6], and thus consid-
ered as a “semi-proxy” for a NAb assay. Using this assay, anti-natalizumab ADA has been
reported to develop in 4.5–12% of treated patients [6,7]. Assays for measuring drug levels of
IFNβ or natalizumab have not been used in any of the countries.
Data on ADA and NAb have been collected over several years in Europe, but a systematic
comparison between countries regarding number of patients and tests, and use of different
drug preparations over time has not been performed previously. Here we present the most
extensive amount of post-marketing immunogenicity data for MS patients treated with IFNβ
and natalizumab in Europe. Collaborative analysis of this data may allow new insights into
clinical relevance of ADA testing, in how ADA monitoring has been integrated in treatment
decisions, and what may be the unmet future needs in immunogenicity related research.
Hence, the objective of this study was to integrate all retrospective ADA data available to
the Anti-Biopharmaceutical Immunization: prediction and analysis of clinical relevance to
minimize the RISK (ABIRISK)-EU consortium in the MS field (www.abirisk.eu) in a common
database, describing and comparing results from monitoring of ADA in MS patients treated
with IFNβ or natalizumab, and to report on type of ADA assay used over time, time of sample
collection for analysis, and treatment duration and age at time of testing.
Materials and methods
Collection of data
Retrospective data on ADA tested patients were collected from seven cohorts in Europe and
standardized to a common data format loosely based on the CDISC standards (www.cdisc.
org). Where no previous variable description could be found in CDISC, a local variable
description was used. All variables were described in a data load plan that was used by all data
custodians when preparing data. Anonymized data from the different cohorts was merged and
uploaded into the translational data analysis platform tranSMART [8]. For advanced analysis,
data was exported and analyzed using R [9]. All sites requiring had approval from local ethics
committees for uploading anonymized data.
The uploaded data from 20,695 patients and 42,555 samples contained both patient specific
demographics such as age, gender, date of first IFNβ prescription, whether the patient was
treatment naive at first test for ADA, treatment information at each date of sampling, type of
assay used, and test result (i.e. negative/positive/titer level). After quality control of the data a
total of 20,115 patients and 41,339 samples remained for analysis (S1 Fig)
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Description of cohorts
Sweden. Testing for IFNβ NAb was initiated 2003 in Sweden, and clinics from all over the
country were encouraged to sample all patients on IFNβ treatment. In 2010 it was recom-
mended, based on the publication by Polman et al, that switching to a non-IFNβ treatment
should be considered if a NAb positive test with a titer above 600 ten-fold reduction units per
milliliter (TRU/ml) was registered [10]. Testing for ADA against natalizumab was initially free
of charge (courtesy of Biogen Idec) in Sweden between 2006 and 2011, and clinics were
encouraged to send samples for ADA testing at baseline before first infusion and every six
months following treatment start. All samples were sent to one nationwide reference labora-
tory at Karolinska Institutet in Stockholm, and data on all ADA-tested samples in Sweden
between 2001 and 2013 are included in this study. For the Swedish cohort the study was
approved by the regional ethical committee in Stockholm, Sweden, and approval for export of
data from the national Multiple Sclerosis Registry (www.neuroreg.se) was given by the
Research Board of the Swedish MS Society.
Austria. Throughout Austria, testing for NAbs against IFNβ was initiated 1995 and ADA
testing of natalizumab- treated patients was introduced in 2006. All samples were sent for
ADA testing at the discretion of doctors to a reference laboratory in Innsbruck where testing
for ADA was part of a scientific project supported by unrestricted grants from industry.
Results from all samples tested between 1995 and 2014 are included in this study. Retrospective
analyses based on anonymous data that have been collected during routine procedures do not
require ethical approval in Austria.
Denmark. In Denmark, IFNβ NAb testing has been part of the clinical routine since 1996
and ADA test for natalizumab was also introduced in 2007. For this study, only results from
IFNβ NAb tests performed with the same Luciferase assay method between 2009 and 2014
were included. Before 2009 IFNβ NAb was analysed by Klaus Bendtzen, Rigshospitalet, and
later by Biomonitor. At Rigshospitalet, an ELISA was used to screen for ADA from 2005 to
2009, and for confirmation of ADA from 2009 to 2012. Analysis with the myxovirus resistance
protein A (MxA) gene expression assay (MGA) for final confirmation of ADA-positive sam-
ples before cessation of IFNβ treatment was an option used from 2005. The MGA was calcu-
lated as an index based on the expression of MxA and the endogenous control GAPDH, with
NAb-positive samples having a relative MxA expression less than 5 and NAb-negative above
15. Samples tested for ADA against natalizumab were analyzed after 2007. Only data from
patients who approved participation in the Danish Multiple Sclerosis Biobank were included
from 2007–2014. Patients and samples for which important information were missing was
excluded. For IFNβ, the included data constituted 39% and 42% of the total number of patients
and measured samples, respectively. For natalizumab, 73% of patients and 89% of total mea-
sured samples were included. All tests were performed in one central reference laboratory at
Rigshospitalet in Copenhagen. The Danish MS cohort collected in the Danish Multiple Sclero-
sis Biobank was approved by the regional scientific ethical committee in Copenhagen and
Frederiksberg, Denmark, and approval for use of data was given by the Danish Data Protection
Agency in the Capital Region, Denmark.
Germany. In Germany, a two-tiered testing approach was used in which samples were
first screened for ADA against IFNβ and positive samples were subsequently tested for NAbs
against IFNβ. Results from ADA tests against natalizumab were not available for this study.
In Dusseldorf, test results and anonymized data from the German central laboratory for
NAb testing were included in this study. To ensure similar testing protocols for all samples,
only data from 2008 to 2014 were included. Analysis was performed at the discretion of the
treating physician, and included follow-up testing.
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In Munich, ADA and NAb testing of IFNβ started in 2003 and all patients tested until 2008
are included in this study. The data from Munich were originated from the German reference
laboratory with a nationwide collection and all samples included in this cohort were part of a
research project. One sample per patient was provided from this cohort. For the Munich
cohort the study was approved by the ethical committee of the School of Medicine of the Tech-
nical University of Munich, Germany.
Switzerland. In Switzerland, samples from IFNβ-treated patients with a suspicion of
NAbs were sent to a reference laboratory in Italy for NAb testing (Dr. Bertolotto; Centro di
Riferimento Regionale Sclerosis Multipla, Orbassano, Turin, Italy). A collection of patients
with samples tested between 2005 and 2009 was part of this study. No results from testing for
ADA against natalizumab were provided. The use of anonymous data for retrospective analysis
did not require ethical approval in Switzerland at the time of sampling.
Spain. Spanish MS patients included in the study were tested for NAb against IFNβ
between 1996 and 2005. No data on anti-natalizumab ADA testing was provided. The Spanish
cohort was collected in a research laboratory at the Centre d’Esclerosi Mu´ltiple de Catalunya
(Cemcat) in Barcelona, and two tested samples per patient were provided. For the Spanish
cohort the study was approved by the Hospital Vall d’Hebron ethical committee in Barcelona,
Spain.
ADA testing
Capture ELISA for testing of ADA against IFNβ was used in the German cohorts and served as
a screening method to identify which samples to test for NAbs [11]. Reactivity above 25% of
the highest positive control was considered to be antibody positive in the ELISA.
ADA testing for natalizumab was performed in Austria, Denmark and Sweden using the
same validated protocol and standardized bridging ELISA method developed by Biogen Idec
as previously described [6]. Samples were considered positive if antibody levels equal to or
above 0.5 μg/mL were detected and further that the ratio of absorbance optical density values
between background and sample was less than 0.5. In this assay, positivity is set at a level corre-
sponding to reduced efficacy of the drug and discontinued treatment is recommended if
patients are confirmed to be persistently positive, i.e. two positive samples taken at least six
weeks apart [6]. For this study, any time positive after treatment initiation was considered as a
positive ADA result.
NAb testing
Samples tested for NAbs against IFNβ have been analyzed using different methods and proto-
cols, both within cohorts over time and between cohorts (Fig 1).
NAb testing with the MxA protein expression assay (MPA) or MGA were used in Sweden,
Austria and Switzerland [12–14]. MGA was also used in Spain for a few samples during 1997
and 2003 (not shown in Fig 1) but the majority of samples were analyzed by the CPE method
[15]. Austria, Denmark and Dusseldorf used the Luciferase (LUC) assay according to previ-
ously described protocols [16–18]. In Munich the In Vivo assay was used, in which the biologi-
cal in vivo activity of IFNβ was measured by induction of MxA gene expression and compared
to newly treated antibody-negative control donors [19]. A cross-validation study on 247
samples was performed between Austria and Munich using the MGA assay that showed an
agreement of 96% for classifying samples as NAb positive (>30 TRU/ml) versus NAb
negative (personal communication with F. Deisenhammer). Only in Sweden was the iLite
anti-human IFNβ-1a bioassay used for the latest samples [20]. Over 95% correlation between
NAb titer levels derived from the former MGA and MPA methods as well as between MGA
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and iLite methods has been shown in Sweden. When classifying samples as NAb positive
(>10 TRU/ml) versus NAb negative, the iLite assay showed lower sensitivity by only detecting
16 of the 23 positive samples in the MGA [21]. The Kawade formula was used to adjust NAb
titers obtained with the MPA, MGA, LUC and iLite methods [22]. Titers or neutralizing capac-
ity for positivity in each NAb assay is presented in Table 1. In all analyses, a positive sample
was defined according to the cut-off for NAb positivity used in the respective cohorts, as
shown in Table 1. Unless otherwise specified, all results regarding anti-IFNβ ADA were
Fig 1. Main methods used for NAb testing in different cohorts over time. In cases where two different methods were used in the same year,
only the most frequently used method is shown.
doi:10.1371/journal.pone.0170395.g001
Table 1. Definition of positive samples according to the cut-off for NAb positivity in different cohorts. For MPA, MGA, iLite, CPE and LUC assay the
cut-off values are presented in ten-fold reduction units per milliliter (TRU/ml). For the In Vivo assay, a sample is considered positive for biologically active anti-
bodies if the MxA induction is decreased by more than 50% compared to antibody-negative controls.
Method/cohort Negative Positive Medium positive High positive
Sweden
MPA < 10 TRU/ml  10 TRU/ml  50 TRU/ml  200 TRU/ml
MGA < 10 TRU/ml  10 TRU/ml  50 TRU/ml  200 TRU/ml
iLite < 10 TRU/ml  10 TRU/ml  50 TRU/ml  200 TRU/ml
Austria
MPA < 20 TRU/ml  20 TRU/ml -  100 TRU/ml
MGA < 20 TRU/ml  20 TRU/ml -  100 TRU/ml
LUC < 20 TRU/ml  20 TRU/ml -  100 TRU/ml
Denmark
LUC < 20 TRU/ml  20 TRU/ml - -
Dusseldorf
LUC < 20 TRU/ml  20 TRU/ml - > 100 TRU/ml
Munich
In Vivo < 50% decrease  50% decrease - -
Spain
CPE < 20 TRU/ml  20 TRU/ml - > 100 TRU/ml
Switzerland
MGA < 20 TRU/ml  20 TRU/ml - -
doi:10.1371/journal.pone.0170395.t001
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analyzed using NAb tests. Any time positive was considered as NAb positive in this study.
IFNβ-1a s.c. given in doses 22 μg or 44 μg were analyzed together.
Statistics
Data was processed using standard workflows wherein patients’ visits and tests were catego-
rized according to information available regarding treatment, date, patient age, treatment start
date, etc. Descriptive statistics included calculation of medians and counts of various data sub-
sets. Fisher’s exact test was used to test association for statistical significance within groups at
the 0.05 level when estimating the risk of becoming ADA positive on natalizumab if previously
NAb positive against IFNβ. When testing for sample numbers across ages, the significance of
the slope of the regression line was assessed.
Calculations were made using R 3.2 [23] as well as Python 2.7 and Pandas 0.13.1. All
box plots and graphs were made with matplotlib 1.3.1.
Results
Overall number of ADA tests against IFNβ and natalizumab
The number of samples from MS patients that received IFNβ treatment and were analyzed for
ADA increased from 2002 to 2006 and remained stable with around 2500 samples each year
over the subsequent period of investigation. For natalizumab-treated patients that were tested
for ADA the number of samples increased from 2006 to 2010, when over 2000 samples were
analyzed, and then declined to less than 1000 samples between year 2011 and 2013 (Fig 2).
Comparison of number of ADA tests per patient between countries
A mean of 2.05 samples were tested per patient in all countries and ranged from 1.0 in Munich
to 2.8 in Denmark, reflecting the selection of data included in this study. Details for each coun-
try are shown in Table 2. Approximately half of the patients only had one test, giving a median
of 1 test per patient. The median varied between countries: 2 in Sweden (max = 13), 1 in Aus-
tria (max = 50), 3 in Denmark (max = 9), 1 in Dusseldorf (max = 7), and 1 in Munich
(max = 1).
An extreme case of 50 tests in Austria represents monitoring of a patient that switched
from IFNβ to natalizumab. This patient had nine NAb-negative samples when treated with
IFNβ-1a s.c. (7 tests) and IFNβ-1b-Betaferon (2 tests), with one borderline positive test. After
switching to natalizumab, the initial test after treatment start was positive for anti-natalizumab
ADA. Forty additional tests during treatment with natalizumab taken during the next five and
a half years were all ADA negative.
When examining the number of tests performed and age at sampling, there was no signifi-
cant deviation of the regression line from slope = 0. Therefore, sample numbers were consis-
tent across all ages.
Time from treatment start to first tested sample versus first positive
sample
Most patients had their first ADA test within the first two to four years of treatment (Fig 3).
The longest period was noted for patients treated with IFNβ-1b-Betaferon that was introduced
on the market several years before ADA testing started. The shortest time between treatment
start and first test was observed for IFNβ-1b-Extavia and natalizumab for which ADA tests
were available immediately.
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Fig 2. Overall number of ADA tests against IFNβ and natalizumab over time. This includes all tested samples from every
cohort and not only samples from those cohorts that have data during the entire period of investigation.
doi:10.1371/journal.pone.0170395.g002
Table 2. Description of cohorts.
Country/Cohort Patients (N) Male/
Female






Austria 4582 1377/31581 69.6% 12351 50 2.7 1.0
Denmark 1936 566/1370 70.8% 5517 9 2.8 3.0
Germany/
Dusseldorf
5498 1565/39122 71.4% 6677 7 1.2 1.0
Germany/ Munich 2255 635/16163 71.8% 2255 1 1.0 1.0
Spain 64 22/42 65.6% 128 2 2.0 2.0
Sweden 6189 1753/4436 71.7% 15383 13 2.5 2.0
Switzerland 201 61/140 69.7% 238 3 1.2 1.0
1 47 did not have information on gender
2 21 did not have information on gender
3 4 did not have information on gender
doi:10.1371/journal.pone.0170395.t002
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Fig 3. Time intervals between treatment start and testing for ADA differs between treatments. Years
from treatment start to first sample tested (A), with patient numbers and median time given in S2 Table. Years
from treatment start to first positive test (B), with summary information presented in S3 Table. Results were
obtained from NAb assays for IFNβ and ADA assay for natalizumab.
doi:10.1371/journal.pone.0170395.g003
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The time to first sample (Fig 3) shows similar characteristics as time to first positive sample
(Fig 3), with the group treated with IFNβ-1a i.m having the longest maximum time to first pos-
itive sample and nearly equal median (2.27 years) as IFNβ-1a s.c. (2.09 years) and IFNβ-1b-
Betaferon (1.96 years) (Fig 3). The time to first positive sample for IFNβ-1b-Extavia and natali-
zumab was much shorter (0.94 and 0.23 years, respectively), although the low number of
patients in the IFNβ-1b-Extavia group (42 patients) makes these results more uncertain than
for the natalizumab-treated group (245 patients). The vast majority of the positive samples
were the first sample tested (Fig 3). Patients treated with i.m. IFNβ-1a, s.c. IFNβ-1a and IFNβ-
1b-Betaferon had the longest median times to the first positive sample, and thus they were
administered the drug for a long time despite being ADA positive.
Rates of ADA differ depending on IFNβ preparation
The immunogenicity of the different drug preparations varies and the same trend was con-
firmed in the different countries and cohorts in ranking, but not in absolute percentage. IFNβ-
1a i.m. and natalizumab were the least immunogenic drugs, whereas the highest frequencies of
ADA were observed for the identical IFNβ-1b preparations (Betaferon1 and Extavia1). Before
the new formulation of IFNβ-1a s.c. was released in 2007, the ADA frequency was as high as
for the two IFNβ-1b preparations, but the clear and lasting reduction in positive samples
observed after 2007 could indicate that this formulation was less immunogenic than the previ-
ous one (Table 3).
Comparison between IFNβ ADA assays
In this study, six different assays were used over time to analyze ADA against IFNβ in the dif-
ferent countries (Table 1). A difference in the overall proportion of ADA positive samples was
observed between the assays and ranged from 10.0% for the In Vivo assay to 37.9% for the
CPE assay (Table 4). The variation in ADA detection rate could reflect differences in sensitivity
of the assays, but may also be influenced by the proportion of samples tested against the
Table 3. Percentage of positive samples for each treatment stratified by country. Results were obtained from NAb assays for IFNβ and ADA assay for
natalizumab over the entire time of the study.
Treatment Austria Denmark Germany/ Dusseldorf Germany/ Munich Spain Sweden Switzerland
IFNβ-1a i.m. 6.9 3.5 7.8 2.8 8.8 9.9 13.3
IFNβ-1a s.c. 23.4 15.0 26.9 11.5 29.4 34.0 23.6
IFNβ-1b-Betaferon 25.3 14.8 40.4 13.3 68.3 48.7 28.6
IFNβ-1b-Extavia - 23.9 37.5 - - 40.2 -
Natalizumab 6.1 5.4 - - - 2.5 -
doi:10.1371/journal.pone.0170395.t003
Table 4. Proportion of ADA positive samples detected for each assay stratified by IFNβ preparation.
IFNβ-1a i.m. IFNβ-1a s.c. IFNβ-1b-Betaferon IFNβ-1b-Extavia All preparations
Assay Positive Total Positive Total Positive Total Positive Total Positive Total
CPE 3 (8.8%) 34 10 (31.3%) 32 31 (62.0%) 50 0 (n.a.) 0 44 (37.9%) 116
LUC 249 (9.0%) 2777 930 (35.6%) 2613 1025 (52.8%) 1943 115 (56.1%) 205 2319 (30.8%) 7538
MPA 221 (9.5%) 2319 1128 (33.1%) 3408 781 (29.9%) 2611 0 (n.a.) 0 2130 (25.5%) 8338
MGA 188 (8.5%) 2207 406 (23.9%) 1701 686 (42.8%) 1601 45 (44.1%) 102 1325 (23.6%) 5611
iLite 15 (5.0%) 299 26 (21.1%) 123 25 (28.4%) 88 27 (36.0%) 75 93 (15.9%) 585
InVivo 15 (2.8%) 540 92 (11.5%) 799 106 (13.4%) 792 0 (n.a.) 0 213 (10.0%) 2131
doi:10.1371/journal.pone.0170395.t004
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different IFNβ preparations as they vary in immunogenicity. In fact, the high ADA detection
rate of the CPE assay could to some extent be influenced by a relatively higher proportion of
samples from patients treated with the more immunogenic IFNβ-1b-Betaferon preparation
compared to the less immunogenic IFNβ-1a i.m. preparation (43% vs 29%). For the iLite
assay, the opposite proportions between the most immunogenic (IFNβ-1b-Betaferon and
IFNβ-1b-Extavia) and least immunogenic (IFNβ-1a i.m.) preparations (28% vs 51%) may
partly explain the low detection rate observed for the iLite assay (S1 Table). Nevertheless, after
stratification for IFNβ preparation the same trend was observed across the assays, with IFNβ-
1a i.m. being the least immunogenic and the two IFNβ-1b s.c. preparations being the most
immunogenic, except for the MPA assay where the ADA frequency was highest for the IFNβ-
1a s.c. preparation (Table 4).
Development of ADA against natalizumab after previous anti-IFNβ ADA
positivity
Patients that had been tested for ADA against both IFNβ and natalizumab after treatment start
were investigated to determine if ADA positivity to IFNβ was associated with subsequent
development of anti-natalizumab ADA. Among patients tested for ADA against both treat-
ments (n = 1414), 82 of 1070 (7.6%) anti-IFNβ ADA-negative patients were eventually positive
for anti-natalizumab ADA. Of the 344 anti-IFNβ ADA-positive patients, 18 patients (5.2%)
were also positive for ADA to natalizumab, but a statistically significant association was not
present (p = 0.1467). However, due to low numbers of patients with ADA to natalizumab in
both groups, an association cannot be excluded.
Age and gender of MS patients tested positive for ADA
A higher rate of ADA-positive samples for the IFNβ preparations was observed with age. The
proportion of ADA-positive tests was nearly twice as high in patients older than 60 years com-
pared to those that were younger than 30 years. The percentage of ADA-positive samples was
similar for men and women for both IFNβ and natalizumab (Fig 4).
Discussion
This is the first large scale descriptive study conducted to report how ADA testing against
IFNβ and natalizumab in European patients with MS has been used as routine clinical practice
and as part of research studies. In this large dataset, we were able to confirm the previously
observed differences in immunogenicity between the four IFNβ preparations. The decline in
samples tested for ADA against the more immunogenic preparations IFNβ-1b-Betaferon and
IFNβ-1a s.c. in favor of the least immunogenic preparation IFNβ-1a i.m. during the investi-
gated time period could at least in part be due to the increased awareness of the variation in
immunogenicity between the IFNβ preparations. This was previously reported for the Swedish
population of NAb tested patients treated with IFNβ included here [14], but could now be con-
firmed in a larger cohort including other sites with established methods for routine monitor-
ing of ADA. Nevertheless, the IFNβ preparations with the highest immunogenicity are still
frequently used, indicating that ADA is far from the major factor that guides choice of treat-
ment alternatives. For example, both IFNβ-1a s.c. and IFNβ-1b-Betaferon have been suggested
to be more effective for preventing relapses in relapsing remitting MS patients than IFNβ-1a
i.m. [24–26] and IFNβ-1b-Betaferon might be more effective in slowing down disease progres-
sion in secondary progressive MS patients that still have relapse activity [27]. There are also
indications of that patients treated with IFNβ-1b have a greater chance of reverting to NAb
negativity during continuous treatment [28,29]. Thus, even though ADA testing has become
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an integrated part of treatment decision for MS patients in several parts of Europe, other fac-
tors are also influencing actual clinical practice.
Assays used for ADA detection and quantification can differ in sensitivity, and the same
type of assay method can vary between laboratories depending not only on differences in
reagents and cell culture methods, but also on how the minimal required dilution of serum
and the assay cut-point have been determined. Today there are several assays for IFNβ NAb
testing and in this study five different cell-based assays and one in vivo assay were used. As
expected, the different ADA assay methods that were used over time by the different countries
and cohorts gave different rates of ADA positivity, among which the CPE assay and LUC assay
detected the highest and the In Vivo assay and iLite assay detected the lowest percentage of
positive samples. The variation in ADA detection indicates that the assays differ in sensitivity,
which has also been previously reported for the MGA and iLite assay [21]. In addition, there
are other possible factors that could account for the observed differences. Some of the variation
could reflect that a greater proportion of the analyzed samples were from patients treated with
the most immunogenic preparation IFNβ-1b-Betaferon (e.g. for the CPE assay) or with the
Fig 4. Proportion of ADA-positive tests in different age categories, stratified by treatment and gender. The number of tests
given in patient age intervals for each preparation and by gender. Test numbers are given in S4 Table.
doi:10.1371/journal.pone.0170395.g004
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least immunogenic preparation IFNβ-1a i.m. (e.g. for the iLite assay) and this has changed
over time. For assays that were introduced later, the proportion of patients on less immuno-
genic drugs have increased, giving the impression of lower sensitivity of these assays. For the
LUC assay, the relatively high percentage of ADA positive samples could be influenced by the
fact that some countries using this assay first screened samples for binding ADA with an
ELISA assay before testing for neutralizing ADA, resulting in an enrichment of positive sam-
ples tested with the LUC assay. The low percentage of positive samples detected by the In Vivo
assay has largely to do with the definition of positivity, since a sample is only considered posi-
tive if it significantly reduces the biological effect of IFNβ. The corresponding titer in a cell-
based NAb assay would be in the range of 150 TRU/mL [21,30].
Although the detection rate of ADA varied between the assays, the overall number of ADA
positive samples over time as well as the already established differences in immunogenicity of
the different IFNβ preparations, did not change. Nevertheless, the difference in sensitivity
between ADA assay methods highlights the importance of using the same validated assay
across laboratories to get comparable results when performing ADA testing. One of the first
tasks of the ABIRISK project was to establish and validate assays for binding (manuscript sub-
mitted) and neutralizing ADA against IFNβ [31] and ADA against natalizumab (manuscript
in progress), since methodological variations among different assays can impact the results
reported between studies. The clinical relevance of low titer ADA can be questioned and there-
fore the most sensitive assays may not be required for routine monitoring of ADA in the clinic.
In contrast, in the pharmaceutical industry it is crucial to use highly sensitive assays for immu-
nogenicity risk assessments of newly developed drugs. In research, sensitive assays are neces-
sary in order to detect low titers of ADA to be able to investigate the immunological processes
and genetic factors that could predispose to the development of ADA.
Following previously published recommendations, it is advised to routinely test for anti-
IFNβ NAbs after 12 and 24 months of treatment, and in case of positivity repeated measure-
ments should be performed within three to six months [10,32]. However, the clinical practice
of testing for NAb against IFNβ has varied between countries, ranging from being mandatory
to only being recommended when NAb are suspected or provided as part of a research project.
With this extensive dataset, we were able to investigate how well these recommendations were
followed for the different preparations. The results showed that when there is an established
routine assay for ADA detection, the recommendations for testing are followed fairly well, as
seen for natalizumab for which the test was introduced simultaneously with the release of the
drug on the market. However, for IFNβ there were surprisingly high numbers of patients that
had been treated for many years before having an ADA test for the first time. The delayed test-
ing could be in part due to that these patients have shown a favorable disease course, not indi-
cating any need for treatment change. However, the observation that most patients were
positive already in their first tested sample indicates that patients may have been treated for
many years despite being ADA positive and most likely having had reduced effect of the treat-
ment. Thus, even though the clinical picture might not indicate any treatment failure, the
inability of the IFNβ to reach the IFN-receptor due to blocking by ADA [30,33] makes the con-
tinuous injection of IFNβ unnecessary. Considering that anti-IFNβ NAbs generally develop
between 9–18 months after treatment start [34] and that the median of patients treated with
the IFNβ preparations had their first ADA test after around two years of treatment, a major
fraction of these patients with NAb titers high enough to reduce the biological effect of the
drug could have been switched to a more effective treatment earlier. Similar to natalizumab, in
the group treated with IFNβ-1b-Extavia, a preparation introduced on the market when ADA
testing against IFNβ had already been implemented, the patients had their first sample tested
for ADA after a median of 0.99 years which is in agreement with published recommendations
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[32]. Thus, ADA testing could potentially decrease unnecessary use of inefficient drugs to the
benefit of both the patient and the economy of the health care system.
For natalizumab, the recommended time to first testing varied between countries from
every month to six months or in case of indication of ADA. Most ADA-positive patients
treated with natalizumab were already positive in their first sample taken at a median of three
months after treatment start, as has been found previously [13,35] and is especially relevant for
drugs that are monoclonal antibodies [36–38]. Thus, if ADA testing is in place when a drug is
released, it is possible to detect positivity quite soon after treatment initiation and considerably
reduce time on inefficient treatment. Apart from the unnecessary pain for the patients due to
repeated injections with a drug that has reduced or no effect, the overall economical conse-
quence for the health care system of not including ADA testing in treatment decision can be
estimated from data presented in this study. Considering overall health costs there is a balance
between promoting a general screening for ADA and several factors such as drug costs, costs
for ADA testing, the drug efficacy and the frequency of ADA. For example, it has been sug-
gested that routine monitoring of NAb in patients treated with IFNβ-1a i.m. may not be justifi-
able from an economic perspective since the frequency of NAb repeatedly have been found to
be low and the number of identified ADA-positive patients switching treatment has to be com-
pared to the cost of general ADA screening [39]. However, as an example from the data pre-
sented here, of the five individuals who had their first positive test for IFNβ-1b-Betaferon at 15
years or longer after treatment initiation, only one had previous tests, which were negative or
borderline before the present positive test. The other four patients were positive in their first
tests, and therefore may have been positive many years earlier. One reason for this long time
before testing could be that the patients were only tested if there was any indication of treat-
ment failure. This might be costly though. With an average of 17.65 years until the first positive
test in these patients, and assuming they became positive within the first two years of treatment
[34], they have had less efficient treatment for over a decade. With the yearly cost of IFNβ-1b-
Betaferon treatment ranging from $16,000–$25,000 [40,41], the total cost of a patient found
positive after two years of treatment would be up to $391,250 (15.65 x $25,000) per person.
These types of overall health care costs and benefits have to be considered for all current used
BPs individually in conjunction with costs for ADA screening, but might be especially benefi-
cial for very expensive drugs if these are monoclonal antibodies where ADA can be detected
early after treatment initiation.
Extrapolating the reasoning to a European scale by using data on prices of therapies in Swe-
den from 2016, combined with the data on positive tests from Fig 3, gives an estimate of
approximate cost savings created by testing patients for anti-IFNβ NAbs as well as the possible
costs incurred by less stringent testing regiments previously. By using the current prices of
each therapy and the extrapolated cost for the total period and per 1000 MS patients with a
similar distribution of treatments over the 18 years of data in Fig 3, €35,106,852 (1€ = 0.10745
SEK) was spent on therapies after NAb positivity was expected. If half of these NAb-positive
patients given therapy after one year had ineffective treatment due to high titers of neutralizing
ADA, a total of €17,553,426 was spent that could have been redirected toward more effective
health care or other therapeutics. This corresponds to €418,896 per 1000 MS patients each year
that was misdirected, a figure that can be used to estimate potential national savings in health
care costs by introducing ADA routine testing in relation to number of MS patients on treat-
ment, and compared to cost of screening for ADA. In Sweden, data from the national MS reg-
istry shows that over 3,500 MS patients have been treated with IFNβ each year the last 10 years,
and thus accumulated cost of €14 million could have been saved by having a highly efficient
NAb testing routine and strict compliance to the recommendations.
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Another means of avoiding patients becoming inefficiently treated due to ADA is to iden-
tify risk factors predicting susceptibility to ADA development and consider these already
before start of therapy. In this study we assessed whether MS patients that have been previously
positive for anti-IFNβ NAb were more likely to develop anti-natalizumab ADA. As previously
reported in a Danish study on 318 consecutive patients treated with both IFNβ and natalizu-
mab [42], we did not find an association between development of anti-IFNβ NAb and ADA
against natalizumab.
We observed a higher rate of ADA-positive tested samples for the IFNβ preparations with
older age. Even though this study was not appropriately designed to detect age and gender as
true risk factors for ADA, it is clinically useful to see that samples from older patients might
give a higher ADA frequency compared to those reported from clinical trials. To specifically
address the impact of age and gender, as well as other factors on the risk of developing ADA
against IFNβ and natalizumab, the focus of the study should be on a cohort of naive patients
with tests performed during the window of time for ADA appearance.
In conclusion, by characterizing ADA test results from the last decade from several coun-
tries in Europe, we have shown that by having a strategy for ADA testing in place when a drug
is released it is possible to ascertain positivity earlier which could promote therapy changes
and shorten the time that ADA-positive patients stay on less effective treatments. Thus, since
the immunogenicity of BPs can be detected by ADA tests, there is room for improving the effi-
cacy in health care by integrating this aspect in clinical practice.
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